Publications by authors named "P Tejada"
Purpose: To evaluate rates of germline pathogenic/likely pathogenic variants (PVs) and genetic counseling by ancestry in patients with epithelial ovarian cancer (EOC).
Methods: Patients with pathologically confirmed EOC who underwent clinical tumor-normal sequencing from January 1, 2015, to December 31, 2020, inclusive of germline analysis of ≥76 genes were included. Patients with newly identified PVs were referred for Clinical Genetics Service (CGS) counseling.
Background: Germline risk assessment is increasing as part of cancer care; however, disparities in subsequent genetic counseling are unknown.
Methods: Pan-cancer patients were prospectively consented to tumor-normal sequencing via custom next generation sequencing panel (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) inclusive of germline analysis of ≥76 genes from January 2015 through December 2019 (97.5% research nonbillable) with protocol for genetics referral.
Purpose: This study aimed to evaluate uptake and follow-up using internet-assisted population genetic testing (GT) for BRCA1/2 Ashkenazi Jewish founder pathogenic variants (AJPVs).
Methods: Across 4 cities in the United States, from December 2017 to March 2020, individuals aged ≥25 years with ≥1 Ashkenazi Jewish grandparent were offered enrollment. Participants consented and enrolled online with chatbot and video education, underwent BRCA1/2 AJPV GT, and chose to receive results from their primary care provider (PCP) or study staff.
Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates early-onset colorectal cancer (EO-CRC) to see if it's different from average-onset colorectal cancer (AO-CRC) in terms of clinical and genomic features.* -
- Researchers analyzed data from 759 EO-CRC patients (under 50) and 687 AO-CRC patients (50 and older), finding that EO-CRC commonly presents with left-sided tumors, rectal bleeding, and abdominal pain.* -
- While initial differences in genetic alterations were noted, detailed analysis showed no significant gene or pathway differences between EO-CRC and AO-CRC, though more germline pathogenic variants were found in younger patients.*